Wedbush analyst Liana Moussatos reiterated a Hold rating on Regulus (RGLS) today and set a price target of $2. The company’s shares opened today at $1.08, close to its 52-week low of $0.80.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -6.3% and a 38.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Regulus is a Hold with an average price target of $2.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.48 and a one-year low of $0.80. Currently, Regulus has an average volume of 320.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
